Stereotactic ablative radiotherapy (SABR) may offer potential benefit for patients with oligometastatic cancers. The SABR technology is still evolving, and there is still uncertainty about whether or not this treatment will be effective. Moreover, SABR requires considerable infrastructure investment and human resources. Our analysis will evaluate the cost-effectiveness of SABR in BC.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.